Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models".
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 23704554.
- Also identified by DOI 10.1126/science.1233937.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Cramer et al. (Reports, 23 March 2012, p. 1503; published online 9 February 2012) tested bexarotene as a potential β-amyloid-lowering drug for Alzheimer's disease (AD). We were not able to reproduce the described effects in several animal models. Drug formulation appears very critical. Our data call for extreme caution when considering this compound for use in AD patients.
Medical subject headings
- Alzheimer Disease
- Amyloid beta-Peptides
- Apolipoproteins E
- Brain
- Tetrahydronaphthalenes